NTT DATA Launches First Self-Designed DATATRAK eClinical Project Into Production in Japan

NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan

Clinical trial design completed in Kanji interface; Paves the way for multiple independent deployments of clinical trials in Japan by NTT DATA following Enterprise Transfer
 
    CLEVELAND and TOKYO, Nov. 21 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported that its alliance partner in Japan, NTT DATA Corporation, has placed its first self-designed project using the DATATRAK eClinical platform into production for a Japanese clinical trial.  The successful rollout of this first independently designed clinical trial followed a successful completion of an Enterprise Transfer Program from DATATRAK.      
    Through DATATRAK's Enterprise Transfer Program, any client can become independent in the rollout of electronic clinical trials with the Company's eClinical platform.  At this time, all Enterprise Transfer clients continue to host their projects through DATATRAK's state-of-the-art global data center; however, because of advancements with the eClinical platform from the Development Team, it will soon be possible for clients to utilize an optional business approach of hosting their own studies and licensing the product suite for multi-year periods.
    "The strength of the product suite from DATATRAK and their valuable experience in performing many global clinical trials was critical to the success of our joint efforts with this project for our Japanese customer," stated Hiroto Ohno, Senior Manager of Healthcare System Sector for NTT DATA Corporation.  "We look forward to deploying many more electronic clinical trials in this market with DATATRAK eClinical." 
    "Our Team has been working closely with NTT DATA with the goal of empowering them to be independent with our platform so that both companies can gain increasing traction in the Japanese clinical trial market," stated Dr. Jeffrey A. Green, Chief Executive Officer of DATATRAK International, Inc.  "This month, the Teams at both companies were successful at accomplishing this milestone with what turned out to be a very complex clinical trial design.  Because of the experiences learned by all, subsequent clinical trial deployments will be even more efficient in deployment as NTT DATA continues to make excellent progress in this specific geographic market."
 
    About DATATRAK International
    DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry.   The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients.  The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies.  DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas.  Its common stock is listed on the NASDAQ stock Market under the ticker symbol "DATA".  Visit the DATATRAK International, Inc. web site at www.datatrak.net.
   
    Except for the historical information contained in this press release, the statements made in this release are forward-looking statements.  These forward-looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets.  This list of factors is not all inclusive.  In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement.